Cite

HARVARD Citation

    Vergote, I. et al. (n.d.). 00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS. International journal of gynecological cancer. pp. 70-71. [Online]. 
  
Back to record